MedTrace Logo

Peginterferon Alfa-2a, Ribavirin and Epoetin β in Coinfected Patients HCV/HIV Not Responding to Previous Treatment Regimens

NCT00470210 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2019-12-05

No results posted yet for this study

Summary

This trial will assess the sustained virologic response to treatment with peginterferon alfa-2a combined with high-dose ribavirin in human immunodeficiency virus (HIV)-infected patients with hepatitis C virus (HCV) genotype 1 or 4 coinfection and persistent transaminase elevations. These patients will have been nonresponders to previous regimens with peginterferon alfa and ribavirin therapy at a dosage of 800-1200 mg/d.

Conditions

  • Hepatitis C
  • HIV Infections

Interventions

DRUG

Peginterferón alfa-2a (40 KD) (Pegasys®) 180 ug/week

Peginterferón alfa-2a (40 KD) (Pegasys®) 180 ug/week

DRUG

Ribavirin (Copegus®) 1600 mg/day

Ribavirin (Copegus®) 1600 mg/day

DRUG

Epoetin β (450 UI/kg/week)

Epoetin β (450 UI/kg/week)

Sponsors & Collaborators

  • Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia

    collaborator OTHER

  • Germans Trias i Pujol Hospital

    lead OTHER

Principal Investigators

  • Bonaventura Clotet, MD, PhD · Germans Trias i Pujol Hospital

  • Cristina Tural, MD, PhD · Germans Trias i Pujol Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-05-31
Primary Completion
2009-06-30
Completion
2009-06-30

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00470210 on ClinicalTrials.gov